Comparison of Vision and Development Outcomes in Laser- and Bevacizumab-Treated Infants With Retinopathy of Prematurity

Trial Profile

Comparison of Vision and Development Outcomes in Laser- and Bevacizumab-Treated Infants With Retinopathy of Prematurity

Recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Retinopathy of prematurity
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2017 Planned number of patients changed from 100 to 150.
    • 10 Oct 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 03 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top